The Future of Cancer Treatment: Cutting-Edge Advances in Immuno-Oncology
November 8, 2024
Imagine a future where cancer treatment is as precise and personalized as it is powerful, where the body’s own defenses are guided to hunt down and destroy tumors. This vision is becoming reality through immuno-oncology (IO), a transformative field empowering the immune system to selectively attack cancer cells. Unlike traditional treatments like chemotherapy and radiation, […]
Charting New Frontiers in GvHD Treatment: Insights from Niktimvo™ FDA approval
September 4, 2024
On August 14, 2024, Syndax and Incyte announced the FDA approval of Niktimvo™ (axatilimab-csfr), a CSF-1R monoclonal antibody, for the treatment of chronic graft-versus-host disease (GvHD). Axatilimab is the first CSF-1R monoclonal antibody to receive approval, specifically targeting the drivers of inflammation and fibrosis in chronic GvHD (Business Wire, 2024). CSF-1R, a cell surface protein, […]
